Characteristics and comorbidities of the ESPOIR and DESIR cohorts
| ESPOIR (Nr=689) Patients with ERA | DESIR (Nr=645) Patients with ESpA | |
|---|---|---|
| N (%) or mean±SD | N (%) or mean±SD | |
| Male gender | 161 (23.4) | 304 (47.1) |
| Age (years) | 48.2±12.1 | 32.8±8.4 |
| Symptoms duration (weeks) | 14.2±14.5 | 79.0±45.7 |
| Alcohol use | 105 (15.2) | 94 (14.6) |
| ESR* | 30.4±24.8 | 14.2±16.3 |
| CRP† | 22.6±33.9 | 9.4±15.0‡ |
| At least one comorbidity | 294 (42.7) | 131 (20.3) |
| Arterial hypertension | 125 (18.1) | 33 (5.1) |
| Receive treatment (%) | 93.6 | 54.5 |
| Hypercholesterolaemia | 101 (14.7) | 42 (6.5) |
| Receive treatment (%) | 69.3 | 2.4 |
| Hypertriglyceridaemia | 21 (3.0) | 18 (2.8) |
| Dysthyroidism | 82 (11.9) | 24 (3.7) |
| Previous tuberculosis | 32 (4.6) | 6 (0.9) |
| Diabetes mellitus | 28 (4.1) | 6 (0.9) |
| Previous solid malignancies | 24 (3.5) | 3 (0.5) |
| Previous lymphoma | 4 (0.6) | 2 (0.3) |
| Coronary heart disease | 6 (0.9) | 0 |
| Stroke | 4 (0.6) | 0 |
| Peptic ulcer | 35 (5) | 26 (4) |
| Previous gastrointestinal bleeding | 8 (1.2) | 12 (1.9) |
| Hepatitis B | 4 (0.6) | 3 (0.5) |
| Hepatitis C | 6 (0.9) | 1 (0.2) |
*ESR normal <20 mm/1 h.
†CRP normal <10 mg/L (ESPOIR), <6 mg/L (DESIR).
‡N=531.
CRP, C reactive protein; DESIR, Devenir des Spondylarthropathies Indifférenciées Récentes; ERA, early rheumatoid arthritis; ESpA, early axial spondyloarthritis; ESR, erythrocyte sedimentation rate; ESPOIR, Etude et Suivi des Polyarthrites Indifférenciées Récentes.